Not all products or features are available in all markets.

  • Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel
Press Releases

GE Healthcare Life Sciences releases software for cell therapy workflow

December 02, 2019

Software offers customized profile set-up, simplifies process validation, and minimizes variability in cell transduction via spinoculation

 

December 2, 2019 - GE Healthcare Life Sciences continues to build out its flexible solutions across the cell therapy workflow with the commercial availability of SpinOculation C-Pro Protocol Software. Part of the Sepax™ C-Pro Cell Processing System, the software closes and automates the cell transduction step. When used in combination with the Sepax C-Pro instrument and CT-60.1 single-use kit, the software enables users to choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.

 

Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences, said: “Cell therapy manufacturing is complex and requires advanced technologies. GE Healthcare Life Sciences continues to invest and develop the digital solutions needed to advance cell and gene therapies. The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next generation therapeutics.”

Illustration shows the steps in the general workflow of cell processing gene transfer.

 

Additionally, the SpinOculation C-Pro Protocol helps users:

 

Gain reproducibility in transduction steps with an automated and closed solution Save time in the manufacturing process by reducing manipulations Optimize transduction performance by adjusting open system parameters Simplify process validation by not using transduction enhancers

 

Marine De Lageneste, Development Engineer, R&D, Cell & Gene Therapy will answer questions at the Cell Therapy Manufacturing & Gene Therapy Congress for the poster titled “Closed and automated CAR-T cell lentiviral transduction by spinoculation.’’ The Congress takes place in Amsterdam, Netherlands from 3-6 December 2019.

 

The SpinOculation C-Pro application software is available worldwide.

 

About GE Healthcare Life Sciences

 

GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

 

Media Contact:

 

Colleen Connolly

 

Senior Communications Manager, Life Sciences

 

Colleen.Connolly@ge.com

 

M: 774 245 3893

This press release is GE HealthCare historical archive material. Any reference in these materials to GE HealthCare products or their uses may not reflect current medical knowledge or up to date documentation for the products. Do not rely upon this release as a source of information on the safety or effectiveness of the products or on the contents of any product label or manual. Please refer to the current product documentation, including product labels and manuals, for current product information.

Copy article text Link copied to clipboard

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

 

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

 

Follow us on LinkedIn, FacebookInstagram, or visit our website for our latest news and perspectives